The pCPA’s 2025–26 impact report now available
The pCPA is pleased to share its 2025–26 impact report, Ready for the Road Ahead.
The pCPA helped public drug plans save over $5 billion
The pCPA reached new heights when it comes to savings for public drug plans in 2025–26.
Help shape the expansion of the early negotiation process!
We’re exploring ways to expand the early negotiation process (ENP), and we want to hear from you.
Extended agreement for generic drug pricing
The pCPA and the CGPA have extended their agreement on a pricing initiative for generic drugs to 2028.
Introducing our new website!
New look, new features, and more ways to share information.
Driving Change, Delivering Impact
Our 2026–29 strategic plan provides direction for the pCPA’s continued evolution.
One year on the job: Interview with our CEO, Mauro Chies
To celebrate his first year, our CEO reflects on what he’s learned since joining the organization, as well as his plans for the next year and beyond.
pCPA deputy CEO to serve as co-chair of ISPOR roundtable
The pCPA is excited to announce Dominic Tan has been appointed co-chair of the HTA Roundtable at the North American branch of ISPOR.
End-of-year message from Mauro Chies
Reflecting on 2025, a year of big progress and big steps for the pCPA.
Our new expedited negotiation pathways have launched
The pCPA is thrilled to expand its negotiation options with the launch of expedited negotiation pathways are designed to accelerate negotiation timelines.